



Strategy, advocacy and partnering for the orphan drug industry



12-14 November | Hotel SOFIA  
Barcelona

@ORPHAN\_DRUGS

**Event:** The World Orphan Drug Congress 2019

**Dates:** 12-14 November 2019

**Location:** Hotel SOFIA Barcelona

**Website:** <https://www.terrapinn.com/conference/world-orphan-drug-congress/>

**About:**

The 10th [World Orphan Drug Congress](#) is taking place **12th–14th November, 2019** in Barcelona, Spain; and is not an event to be missed.

Now recognised as the **largest and most established European orphan drug event**, we are once again proud to deliver another outstanding speaker line-up and a content-filled agenda that represents the whole orphan drug landscape. The 12th annual event will address the strategic and commercial aspects of bringing new treatments to **patients** who suffer from rare diseases.

For 2019 we will be expanding the meeting further with a dedicated **co-conference** on [Cell & Gene Therapy](#) and even more dedicated content and tracks than ever before on **Clinical/Product Development, Market Access & Pricing, Manufacture, Science & Strategy, Pitch & Partner and Precision Medicine**. We will also continue the highly popular Pre-Congress Workshops.

Download Full agenda [here](#)

Book your ticket [here](#)

**Top speakers:**

Andrzej Rys, Director, Health Systems, Medical Products and Innovation, DG SANTE  
European Commission

Kristina Larsson, Head of Orphan Drugs, EMA

Bernard J. Grimm, Director, Healthcare Biotechnology, Europabio

Delphine Roulland, Director Government Affairs & Public Policy, EUCOPE

Ulrika Vestin, Swedish Association of Local Authorities and Regions (SKL),

Prof Maurizio Scarpa, Coordinator, European Reference Network for Hereditary Metabolic Diseases (MetabERN)

Anne Pariser, MD, Director, Office of Rare Diseases Research, National Center for Advancing Translational Sciences (NCATS), National Institutes of Health

Dr Vinciane Pirard, Co-Chair of Rare Disease & OMP Joint Task Force EFPIA-Europabio & Senior Director Public Affairs, Sanofi

Mark Rothera, Chief Executive Officer, Orchard Therapeutics

Stuart Peltz, Chief Executive Officer, PTC Therapeutics

Bob Smith, Senior Vice President, Global Gene Therapy Business, Pfizer

Sander van Deventer, Chief Scientific Officer, UniQure

Frederic Chereau, Chief Executive Officer, LogicBio Therapeutics

Marcus Guardian, Chief Operating Officer, EUnetHTA